title: Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase.
abstract: 1. Dimethylarginine dimethylaminohydrolase (DDAH), an enzyme that metabolizes the endogenous nitric oxide synthase inhibitors NG-monomethyl-arginine and NG,NG-dimethy-L-arginine to citrulline, was identified by Western blotting in rat and human tissue homogenates. 2. S-2-amino-4(3-methylguanidino)butanoic acid (4124W) inhibited the metabolism of [14C]-NG-monomethyl-L-arginine to [14C]-citrulline by rat liver homogenates (IC50 416 +/- 66 microM; n = 9), human cultured endothelial cells (IC50 250 +/- 34 microM; n = 9) and isolated purified dimethylarginine dimethylaminohydrolase. 3. Addition of 4124W to culture medium increased the accumulation of endogenously-generated NG,NG-dimethy-L-arginine in the supernatant of human cultured endothelial cells from 3.1 +/- 0.3 to 5 +/- 0.7 microM (n = 15; P < 0.005). 4. 4124W (1 microM - 1 mM) had no direct effect on endothelial nitric oxide synthase activity but caused endothelium-dependent contraction of rat aortic rings (1 mM 4124W increased tone by 81.5 +/- 9.6% of that caused by phenylephrine 100 nM). This effect was reversed by L-arginine (100 microM). 4124W reversed endothelium-dependent relaxation of human saphenous vein (19.2 +/- 6.7% reversal of bradykinin-induced relaxation at 1 mM 4124W). 5. These data suggest that inhibition of dimethylarginine dimethylaminohydrolase increases the intracellular contraction of NG,NG-dimethyl-L-arginine sufficiently to inhibit nitric oxide synthesis. Inhibiting the activity of DDAH may provide an alternative mechanism for inhibition of nitric oxide synthases and changes in the activity of DDAH could contribute to pathophysiological alterations in NO generation.
authors.affiliation: Department of Pharmacology and Clinical Pharmacology, St George's Hospital Medical School, London.
authors.forename: R J
authors.initials: RJ
authors.lastname: MacAllister
authors.forename: H
authors.initials: H
authors.lastname: Parry
authors.forename: M
authors.initials: M
authors.lastname: Kimoto
authors.forename: T
authors.initials: T
authors.lastname: Ogawa
authors.forename: R J
authors.initials: RJ
authors.lastname: Russell
authors.forename: H
authors.initials: H
authors.lastname: Hodson
authors.forename: G S
authors.initials: GS
authors.lastname: Whitley
authors.forename: P
authors.initials: P
authors.lastname: Vallance
mesh_terms: D000581:Amidohydrolases; D000613:Aminobutyrates / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D002851:Chromatography, High Pressure Liquid; D002956:Citrulline / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000378:metabolism / Q000494:pharmacology; D005260:Female; D006146:Guanidines / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D006867:Hydrolases / Q000037:antagonists & inhibitors*; D015151:Immunoblotting; D009119:Muscle Contraction / Q000187:drug effects; D009126:Muscle Relaxation / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D009569:Nitric Oxide / Q000096:biosynthesis*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000378:metabolism; D011247:Pregnancy; D051381:Rats; D011921:Rats, Inbred WKY; D014471:Umbilical Veins / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D019323:omega-N-Methylarginine / Q000378:metabolism / Q000494:pharmacology
chemical_list: C514525:2-amino-4-(3-methylguanidino)butanoic acid; D000613:Aminobutyrates; D004791:Enzyme Inhibitors; D006146:Guanidines; D019323:omega-N-Methylarginine; D002956:Citrulline; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; D006867:Hydrolases; D000581:Amidohydrolases; C059999:dimethylargininase